Revisiting: Sample handling between despatch and injection

Posting this under the heading it deserves: Revisiting: Sample handling between despatch and injection Everything below is what sits behind that.

Posting the method first, because I know what the first three replies will otherwise be.

• Column: C18, 2.1 x 100 mm, 1.7 um
• Mobile phase: 0.1% TFA in water / 0.1% TFA in acetonitrile
• Gradient: 12% to 70% organic over 21 minutes
• Detection: 280 nm
• Injection: 20 uL
• Sample: retatrutide, reconstituted to 0.5 mg/mL, injected within an hour

The main peak integrates at 97.8% of total area. There is a small feature on the trailing edge that I cannot decide is a shoulder or a baseline artefact, and that is what I am actually asking about.

I read post #2 twice before replying, because I had assumed the opposite.

Transfer between laboratories: a method can be transferred from one lab to another, but the receiving lab needs to demonstrate that they can achieve the same performance. This requires comparative testing and sometimes small method refinements.

Accuracy: the method measures what you intend to measure. For purity methods, this is tested by spike-and-recover experiments: add a known amount of impurity to a sample and measure whether you recover the added amount.

Picking up post #4: that is the part I would want checked first.

Linearity: the detector response is proportional to compound concentration across the working range. Demonstrated by running standards at multiple concentrations and showing R-squared values typically ≥0.99.

Precision and repeatability: within-run and between-run variability of the method. Acceptance criterion is typically a relative standard deviation of ≤2% for area measurements.